All News

Diabetes Caution: FDA Warns of Risk of Missing Critical Alerts from Smartphone-Compatible Diabetes Devices
February 06, 2025

Hardware or software changes as well as user adjustments may disable or mute alerts for elevated glycemia, medication use, and other diabetes management essentials, the agency said.

New Study Links Major Depressive Disorder to Specific Changes in Eating Preferences
February 06, 2025

People with MDD demonstrated a preference for carbohydrate-rich foods and reduced reward from fat- and protein-rich foods, according to new research.

Viking Therapeutics Advances 3 Potential Obesity Treatments Based on Promising 2024 Clinical Trial Results
February 06, 2025

A GLP-1/GIP dual agonist in both subcutaneous and oral tablet formulations and a novel dual amylin and calcitonin receptor agonist lead the company's pipeline for antiobesity medications.

FDA Greenlights Symbravo for Acute Treatment of Migraine: Daily Dose
February 06, 2025

Your daily dose of the clinical news you may have missed.

Premature Menopause May Increase Risk of Type 2 Diabetes Suggests Study of 1.1 Million Women
February 05, 2025

Premature menopause, authors said, should be included in diabetes management guidelines as a risk factor to support screening and prevention.

Investigators Identify Hemoglobin A1c/HDL-C as a Predictor of Stroke Risk in Older Adults
February 05, 2025

Elevated HbA1c/HDL-C ratios significantly increased stroke risk, even after adjusting for confounding factors, reported authors of a recent study.

Roche Receives FDA 510(k) Clearance for First US Blood Test Measuring Lp(a) in Molar Units
February 05, 2025

The Tina-quant® Lipoprotein (a) Gen.2 Molarity assay measures Lp(a) in molar units, providing a more accurate particle-based risk assessment than mass units.

Study Identifies Key Symptoms of Topical Steroid Withdrawal: Daily Dose
February 05, 2025

Your daily dose of the clinical news you may have missed.

New ACP Guidelines on Prevention of Episodic Migraine Cite Lack of Comparative Evidence for Treatments
February 05, 2025

Pharmacologic treatment to prevent episodic migraine should follow a sequential trial approach that considers medication cost, headache triggers, adherence, and lifestyle interventions.

Delgocitinib Effective in Adolescents with CHE in Phase 3 DELTA TEEN Trial
February 04, 2025

With no FDA-approved treatments for moderate-to-severe chronic hand eczema in the teen population, the late-stage topline data are very promising.